GILD vs. BIIB, AMGN, MRNA, ARGX, BNTX, HCA, GSK, MCK, ZTS, and REGN
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Biogen (BIIB), Amgen (AMGN), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), HCA Healthcare (HCA), GSK (GSK), McKesson (MCK), Zoetis (ZTS), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "medical" sector.
Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
87.9% of Biogen shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Biogen shares are held by company insiders. Comparatively, 0.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Biogen has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Gilead Sciences has a net margin of 20.89% compared to Gilead Sciences' net margin of 12.07%. Biogen's return on equity of 38.85% beat Gilead Sciences' return on equity.
Gilead Sciences received 675 more outperform votes than Biogen when rated by MarketBeat users. Likewise, 77.39% of users gave Gilead Sciences an outperform vote while only 71.86% of users gave Biogen an outperform vote.
Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Biogen currently has a consensus price target of $293.88, suggesting a potential upside of 40.68%. Gilead Sciences has a consensus price target of $83.87, suggesting a potential upside of 28.20%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Biogen is more favorable than Gilead Sciences.
In the previous week, Biogen had 11 more articles in the media than Gilead Sciences. MarketBeat recorded 71 mentions for Biogen and 60 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.39 beat Biogen's score of 0.25 indicating that Biogen is being referred to more favorably in the media.
Summary
Biogen beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gilead Sciences Competitors List
Related Companies and Tools
